Casper E S, Guidera C A, Bosl G J, Hakes T B, Kaufman R J, Shurgot B, Kinne D W
Breast Cancer Res Treat. 1987;9(1):39-44. doi: 10.1007/BF01806692.
Forty-one women with non-metastatic but locally advanced breast cancer were treated by modified radical or radical mastectomy, and were then randomized to receive one of two adjuvant chemotherapy regimens. Regimen A consisted of 6 months of cyclophosphamide, adriamycin, and fluorouracil (CAF) followed by 6 months of cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone (CMFVP). Regimen B was 12 months of CMFVP. Patients were stratified for estrogen-receptor status, and all patients with a positive estrogen receptor value received tamoxifen 20 mg bid in addition to the chemotherapy. Eight of 21 patients randomized to Regimen A are alive and free of disease, whereas only 1 of 20 patients on Regimen B is well. A trend toward improved disease-free survival favoring Regimen A was observed (P = .05), although a significant difference in overall survival has not been demonstrated. Our findings support the continued study of adriamycin-containing regimens in the adjuvant setting and in combined modality therapy of locally advanced breast cancer.
41例非转移性但局部晚期乳腺癌患者接受了改良根治术或根治性乳房切除术，然后随机接受两种辅助化疗方案之一。方案A包括6个月的环磷酰胺、阿霉素和氟尿嘧啶（CAF），随后是6个月的环磷酰胺、甲氨蝶呤、氟尿嘧啶、长春新碱和泼尼松（CMFVP）。方案B是12个月的CMFVP。患者根据雌激素受体状态进行分层，所有雌激素受体值为阳性的患者除化疗外还接受他莫昔芬20mg bid治疗。随机分配到方案A的21例患者中有8例存活且无疾病，而方案B的20例患者中只有1例情况良好。观察到有利于方案A的无病生存期改善趋势（P = 0.05），尽管总体生存期的显著差异尚未得到证实。我们的研究结果支持在辅助治疗环境以及局部晚期乳腺癌的综合治疗中继续研究含阿霉素的方案。
